Target intelligence / Profile preview

C-terminal domain small phosphatase 1 (CTDSP1)

Target
CTDSP1
Molecular classification
Enzyme, Phosphatase, Haloacid dehalogenase-like hydrolase family
01

Overview

C-terminal domain small phosphatase 1 (CTDSP1), also known as SCP1, is a critical enzyme belonging to the haloacid dehalogenase-like hydrolase family that regulates the eukaryotic transcription cycle. Its primary function involves the specific dephosphorylation of the Ser-5 residue within the C-terminal domain (CTD) of RNA polymerase II, which is a vital step for the transition from transcription initiation to elongation (Yeo et al., 2003, UniProt Q9GZU7). CTDSP1 also functions as a transcriptional corepressor by interacting with the REST/NRSF complex to silence neuronal genes in non-neuronal cells, thereby playing a significant role in cellular differentiation (Visvanathan et al., 2007). In clinical oncology, CTDSP1 is often found dysregulated and has been implicated in the progression of various cancers by modulating the cell cycle and signaling pathways like BMP and TGF-beta (Kashuba et al., 2004). Research into small molecule inhibitors has identified compounds such as the proton pump inhibitor rabeprazole that can inhibit CTDSP1 activity, suggesting potential for drug repurposing or the development of novel therapeutics (Zhang et al., 2011). However, because CTDSP1 influences fundamental transcriptional processes, therapeutic strategies must carefully address the risks of broad-spectrum gene dysregulation and off-target effects on related phosphatases.

Other names
SCP1NIF3NLIIFCTD small phosphatase 1Nuclear LIM interactor-interacting factor 3
02

Mechanism of action

Inhibition of CTDSP1 phosphatase activity to modulate RNA polymerase II phosphorylation and gene expression.

03

Biological functions

Transcription regulationCell cycle regulationNeuronal gene silencingSignal transductionRNA processing
04

Disease associations

CancerNeurodegenerative disease
05

Safety considerations

Broad transcriptional dysregulationOff-target inhibition of related CTD phosphatasesPotential systemic toxicity due to fundamental role in gene expression
06

Interacting drugs

Rabeprazole
07

Biomarkers

CTDSP1 protein expression levelRNA polymerase II Ser-5 phosphorylation status

Beyond the preview

Go deeper on C-terminal domain small phosphatase 1 (CTDSP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-terminal domain small phosphatase 1 (CTDSP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call